Sanofi Ventures
VC Fund
Cambridge, United States
Sanofi Ventures is a VC fund in Cambridge focused on Biotechnology and Health Care. Sanofi Ventures is the corporate venture capital arm of Sanofi. We have the ability to seed and to lead financings in early-stage companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. Among these areas are rare diseases, oncology, immunology and inflammation, vaccines, potentialcures in other core areas of Sanofi’s business footprint, and digital health and data science solutions.
- Total investments:
- 128
- Last investment:
- Lead investor:
- 26%
- Fund size:
- $625M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sanofi Ventures invests in
Stages Sanofi Ventures invests in
Countries Sanofi Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $9M–$140M
- Series B
- $30M–$125M
- Series C
- $30M–$120M
Investment Focus
Industry
- Biotechnology 57 (45%)
- Health Care 43 (34%)
- Medical 30 (23%)
- Therapeutics 26 (20%)
- Pharmaceutical 22 (17%)
Stage
- Series B 38 (30%)
- Series A 29 (23%)
- Series C 15 (12%)
- Seed 8 (6%)
- Funding Round 5 (4%)
Country
- United States 58 (45%)
- United Kingdom 4 (3%)
- France 2 (2%)
- Israel 2 (2%)
- Denmark 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christopher Gagliardi
Principal
|
Principal | Total investments: 10 | Find email | |
Alan Walts
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Alba Zurriaga Carda
Director of Investments
|
Director of Investments | Total investments: 0 | Find email | |
Charles Thyne
Industrial Operations
|
Industrial Operations | Total investments: 0 | Find email | |
Cris De Luca
Partner, Digital Investments, Sanofi Ventures
|
Partner, Digital Investments, Sanofi Ventures | Total investments: 7 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Abcuro
|
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $66M / Series D / Aug 18, 2026 | |
Epicrispr Biotechnologies
|
The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent,which means that a single GEMS design can address the majority or all genetic subtypes of a disease. | $90M / Series C / Aug 11, 2026 | |
Expedition Therapeutics
|
Expedition Therapeutics operates as an unincorporated association. | $115M / Series B / Aug 05, 2026 | |
QuantHealth
|
Quant Health offers drug simulation, computational biology, clinical data science, respiratory, trial simulation, and oncology services. | $45M / Series B / Aug 04, 2026 | |
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M / Series D / Jul 15, 2026 | |
Nura Bio
|
Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders. | $73.8M / Series B / Jun 22, 2026 | |
Bionyra
|
Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases. | $165M / Series A / Jun 22, 2026 | |
|
Memento Medicines
|
Memento Medicines is a biotechnology company focused on the development of novel antibody therapies for ophthalmology. The company's core business model centers on licensing and advancing specialized, multi-target biologics to address high-demand clinical needs in the retinal disease landscape. Its primary value proposition rests on its leadprogram, MMT-205, a dual-action bispecific antibody engineered to simultaneously activate Tie2 receptors and inhibit VEGF. This therapeutic candidate is being clinical developed to improve treatment durability and visual outcomes for individuals suffering from neovascular age-related macular degeneration and diabetic macular edema. | $93M / Series A / Jun 18, 2026 | |
BranchLab
|
BranchLab makes healthcare advertising better so that people may find the best healthcare options. | $28.8M / Series A / May 13, 2026 | |
Windward Bio
|
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M / Series B / May 04, 2026 | |
| See all 128 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sanofi Ventures invest in?
Sanofi Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 128 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sanofi Ventures's check size?
Sanofi Ventures typically joins rounds of $9M–$140M at Series A, $30M–$125M at Series B and $30M–$120M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sanofi Ventures participates in.
How do I contact Sanofi Ventures?
Public channels for Sanofi Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sanofi Ventures?
The team at Sanofi Ventures includes Christopher Gagliardi (Principal), Alan Walts (Managing Director) and Alba Zurriaga Carda (Director of Investments), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
